Skip to main
SMMT

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Summit Therapeutics (SMMT) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 25%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Summit Therapeutics Inc. is positioned favorably as it progresses with its lead product candidate, ridinilazole, demonstrating a significant potential in addressing Clostridiodes difficile infections through an innovative antibiotic approach. Recent developments, including positive outcomes from clinical trials and enhanced enrollment protocols, suggest an incremental de-risking of the company's pipeline, particularly with the potential for ivonescimab to establish itself as a competitive treatment option in solid tumors. The avoidance of a Refuse-to-File letter indicates that the company has made strides in advancing its regulatory submissions, further positioning Summit Therapeutics for future growth and opportunities in the biopharmaceutical market.

Bears say

Summit Therapeutics Inc faces significant challenges that contribute to a negative outlook for its stock. The company is exposed to substantial regulatory risks, such as potential delays in research and development, disappointing clinical trial results for ivonescimab, and competition from other drugs, which could adversely impact the sales potential of its product candidates. Furthermore, the historical context indicates that the majority of drugs in clinical development fail to reach the market, highlighting the inherent risk within Summit's current pipeline and future prospects.

Summit Therapeutics (SMMT) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Summit Therapeutics (SMMT) Forecast

Analysts have given Summit Therapeutics (SMMT) a Buy based on their latest research and market trends.

According to 12 analysts, Summit Therapeutics (SMMT) has a Buy consensus rating as of Apr 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Summit Therapeutics (SMMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.